2023 World Conference on Lung Cancer (Posters)-P2.06. Camrelizumab Plus Apatinib as First-Line Treatment for Advanced Squamous Non-small-Cell Lung Cancer: Updated Survival Results of a Phase 2 Trial

P2.06. Camrelizumab Plus Apatinib as First-Line Treatment for Advanced Squamous Non-small-Cell Lung Cancer: Updated Survival Results of a Phase 2 Trial - PDF(Slides)

Back to course

Pdf Summary

A recent phase 2 trial evaluated the combination of camrelizumab and apatinib as a first-line treatment for advanced squamous non-small-cell lung cancer (NSCLC). The study aimed to determine the efficacy and safety of this treatment regimen.<br /><br />A total of 32 patients with advanced squamous NSCLC were enrolled in the trial. The primary endpoint of the study was progression-free survival (PFS), and secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.<br /><br />The results showed promising antitumor activity with camrelizumab plus apatinib as a chemo-free first-line treatment for advanced squamous NSCLC. The overall response rate (ORR) was reported to be 78.1%, and the median PFS was 8.3 months. The median OS was 21.7 months.<br /><br />Subgroup analysis based on disease stage, programmed cell death-ligand 1 (PD-L1) expression, and tumor mutation burden (TMB) revealed that the combination therapy had favorable efficacy across these different subgroups.<br /><br />In terms of safety, the most common grade 3-4 adverse events were proteinuria, increased liver enzymes, decreased platelet count, and interstitial pneumonia. Overall, the combination therapy was well-tolerated.<br /><br />These findings suggest that the combination of camrelizumab and apatinib could be a viable first-line treatment option for patients with advanced squamous NSCLC. Further research and larger clinical trials are needed to validate and expand upon these findings.

Asset Subtitle

Jinliang Wang

Meta Tag

Speaker Jinliang Wang

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

phase 2 trial

camrelizumab

apatinib

first-line treatment

advanced squamous non-small-cell lung cancer

efficacy

safety

progression-free survival

objective response rate

overall survival